Trastuzumab has been the cornerstone of HER2-directed therapy in HER2-overexpressing breast and gastric cancer; however, resistance to trastuzumab or trastuzumab conjugate regimens is universal [18]. The gene discussed is ERBB2; the disease is gastric cancer.